STOCK TITAN
  1. Home
  2. Sec-filings
  3. TERN
  4. [Form 4] Terns Pharmaceuticals, Inc. Insider Trading Activity

[Form 4] Terns Pharmaceuticals, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Terns Pharmaceuticals Chief Financial Officer equity awards On January 14, 2026, Terns Pharmaceuticals, Inc. Chief Financial Officer Andrew Gengos received 68,750 shares of common stock in the form of restricted stock units at a price of $0.00 per share, bringing his directly held common stock to 101,788 shares. The total includes 8,038 shares previously acquired under the company’s 2021 Employee Stock Purchase Plan on November 30, 2025.

On the same date, he was granted a stock option for 137,500 shares of common stock with an exercise price of $37.18 per share. For the RSUs, 25% vest on the first anniversary of January 1, 2026 and the remainder vests quarterly so that all units vest by the fourth anniversary. For the option, 25% of the shares vest on the first anniversary of January 1, 2026, with the rest vesting monthly so that the option is fully vested four years after that vesting commencement date.

Positive

  • None.

Negative

  • None.
Insider Gengos Andrew
Role Chief Financial Officer
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 137,500 $0.00 --
Grant/Award Common Stock 68,750 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 137,500 shares (Direct); Common Stock — 101,788 shares (Direct)
Footnotes (1)
  1. Each share is represented by a Restricted Stock Unit ("RSU"). 25% of the RSUs vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/16th of the total number of shares vest quarterly thereafter, such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date. Includes 8,038 shares acquired by the Reporting Person under the Issuer's 2021 Employee Stock Purchase Plan ("ESPP") on November 30, 2025. 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gengos Andrew
(Last) (First) (Middle)
C/O TERNS PHARMACEUTICALS, INC.
1065 EAST HILLSDALE BLVD., SUITE 100
(Street)
FOSTER CITY CA 94404
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Terns Pharmaceuticals, Inc. [ TERN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
01/14/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/14/2026 A 68,750(1) A $0.00 101,788(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $37.18 01/14/2026 A 137,500 (3) 01/13/2036 Common Stock 137,500 $0.00 137,500 D
Explanation of Responses:
1. Each share is represented by a Restricted Stock Unit ("RSU"). 25% of the RSUs vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/16th of the total number of shares vest quarterly thereafter, such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date.
2. Includes 8,038 shares acquired by the Reporting Person under the Issuer's 2021 Employee Stock Purchase Plan ("ESPP") on November 30, 2025.
3. 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.
Remarks:
/s/ David Strauss, as Attorney-in-Fact for Andrew Gengos 01/16/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR